甲状腺癌放射性碘治疗后继发恶性肿瘤风险的系统综述与荟萃分析
该系统综述与荟萃分析比较了甲状腺癌患者接受放射性碘(RAI)治疗与未接受RAI治疗后继发恶性肿瘤(SMN)的风险。继发白血病风险增加,多发性骨髓瘤风险降低,乳腺癌、唾液腺癌或合并血液系统恶性肿瘤风险无显著增加。证据异质性高,需更多长期研究。
要点
- 继发白血病风险增加,多发性骨髓瘤风险降低,其他特定SMN无显著增加。
核心结论
- 甲状腺癌131I治疗与任何SMN关联的证据高度异质且复杂,需更多长期研究评估特定SMN风险。
研究设计与样本
- 系统综述与荟萃分析,检索6个电子数据库至2018年3月,纳入17项研究(3项系统综述和14项原始研究)。
- 采用随机效应模型对粗数据和经混杂因素统计调整的数据进行荟萃分析。
主要发现
- 继发白血病风险增加,多发性骨髓瘤风险降低;乳腺癌、唾液腺癌或合并血液系统恶性肿瘤的相对风险无显著增加。
局限性
- 证据高度异质(I2=85.99%),发表的知识总结纳入研究数量少,需更多长期特定SMN风险研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: The potential risk of subsequent malignant neoplasms (SMNs) after radioactive iodine (RAI) treatment of thyroid cancer (TC) is an important concern. Methods: A systematic review was updated comparing the risk of SMNs in TC patients treated with RAI to TC patients without RAI. Six electronic databases were searched (up to March, 2018), supplemented with a hand search. Two reviewers independently screened citations, reviewed full-text papers, and critically appraised/abstracted data. Random-effects meta-analyses were conducted using crude data and data statistically adjusted for confounders. The outcomes were any SMN and specific SMNs for which sufficient data were available. Results: In total, 3506 unique electronic search citations and 93 full-text papers were examined, including 17 studies (3 systematic reviews and 14 original studies). Published knowledge syntheses were limited by inclusion of small numbers of studies, with two systematic reviews suggesting an increased risk of any SMN and one meta-analysis suggesting a reduced risk of breast SMN after RAI treatment. In a meta-analysis of crude data, the risk ratio of any SMN in RAI-treated TC patients was 0.98 ([confidence interval (CI) 0.76-1.27]; n = 10 studies of 65,539 individuals, heterogeneity Q = 64.26, degrees of freedom [df] = 9, p < 0.001, I2 = 85.99). The pooled risk ratio for any SMN, adjusted for confounders, was 1.16 ([CI 0.97-1.39]; n = 6 studies, data from at least 11,241 TC patients, Q = 10.86, df = 5, p = 0.054, I2 = 53.96). In secondary analyses examining specific SMNs, although relatively rare, the risk of subsequent leukemia was increased, but the risk of multiple myeloma was reduced in RAI-treated TC patients. There was no significant increased relative risk of breast cancer, salivary cancer, or combined hematologic malignancies according to RAI treatment status. Conclusions: The body of evidence on whether 131I treatment of thyroid cancer is associated with the primary outcome of any SMN is highly heterogeneous and complex. More research examining the long-term risk of specific SMNs after 131I treatment is needed.
引用
- Yu CY, Saeed O, Goldberg AS, et al. A Systematic Review and Meta-Analysis of Subsequent Malignant Neoplasm Risk After Radioactive Iodine Treatment of Thyroid Cancer. Thyroid. 2018. PMID: 30370820. doi:10.1089/thy.2018.0244
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。